Technical Analysis for EBS - Emergent Biosolutions, Inc.

Grade Last Price % Change Price Change
grade F 48.33 -1.31% -0.64
EBS closed down 1.31 percent on Friday, March 22, 2019, on 1.64 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical EBS trend table...

Date Alert Name Type % Chg
Mar 22 180 Bearish Setup Bearish Swing Setup 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 22 Oversold Stochastic Weakness 0.00%
Mar 21 Death Cross Bearish -1.31%
Mar 21 Bullish Engulfing Bullish -1.31%
Mar 21 Inside Day Range Contraction -1.31%
Mar 21 Wide Bands Range Expansion -1.31%
Mar 21 Oversold Stochastic Weakness -1.31%
Mar 20 New 52 Week Closing Low Bearish 0.21%
Mar 20 Calm After Storm Range Contraction 0.21%

Older signals for EBS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Emergent BioSolutions, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. It markets BioThrax, an FDA licensed vaccine for the prevention of anthrax disease; and RSDL (decontamination lotion) product for removal or neutralization of chemical warfare agents from the skin. The company's development pipeline includes Anthrivig (Human Anthrax Immunoglobulin), a polyclonal anthrax therapeutic candidate; PreviThrax, a recombinant anthrax vaccine candidate, NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant); BioThrax with a novel adjuvant; and Thravixa (Fully Human Anthrax Monoclonal Antibody), a therapeutic being studied for use against symptomatic anthrax infection. In addition, it develops TRU-016, a humanized anti-CD37 therapeutic candidate, based on its ADAPTIR (Modular Protein Technology) platform that is in Phase I/II clinical trials to treat chronic lymphocytic leukemia. Further, the company develops preclinical product candidates targeted for solid tumors, inflammatory bowel disease, graft versus host disease, rheumatoid arthritis, and a human vaccine to protect against influenza caused by a range of circulating H5 influenza strains. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Rockville, Maryland.
Medicine Medical Specialties Pharmaceutical Drugs Solid Tumors Influenza Rheumatoid Arthritis Inflammatory Bowel Disease Vaccination FDA Chronic Lymphocytic Leukemia Vaccines Anthrax Biological Warfare Chemical Warfare Agents Preclinical Preclinical Product
Is EBS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 73.89
52 Week Low 46.93
Average Volume 471,178
200-Day Moving Average 60.182
50-Day Moving Average 59.7472
20-Day Moving Average 54.7755
10-Day Moving Average 51.333
Average True Range 2.1859
ADX 31.3
+DI 12.8732
-DI 32.4482
Chandelier Exit (Long, 3 ATRs ) 60.8923
Chandelier Exit (Short, 3 ATRs ) 54.1477
Upper Bollinger Band 63.5552
Lower Bollinger Band 45.9958
Percent B (%b) 0.13
BandWidth 32.057033
MACD Line -3.5218
MACD Signal Line -2.823
MACD Histogram -0.6988
Fundamentals Value
Market Cap 1.99 Billion
Num Shares 41.1 Million
EPS 1.57
Price-to-Earnings (P/E) Ratio 30.78
Price-to-Sales 3.22
Price-to-Book 2.65
PEG Ratio 1.56
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 50.80
Resistance 3 (R3) 51.05 50.48 50.39
Resistance 2 (R2) 50.48 49.85 50.35 50.25
Resistance 1 (R1) 49.40 49.46 49.11 49.15 50.12
Pivot Point 48.83 48.83 48.68 48.70 48.83
Support 1 (S1) 47.75 48.20 47.47 47.51 46.54
Support 2 (S2) 47.18 47.81 47.05 46.41
Support 3 (S3) 46.10 47.18 46.27
Support 4 (S4) 45.86